New anticoagulants for the prevention and treatment of venous thromboembolism

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.

Original languageEnglish
Pages (from-to)461-470
Number of pages10
JournalBiomolecules and Therapeutics
Issue number5
StatePublished - Sep 2017

Bibliographical note

Funding Information:
This work is supported by the National Research Foundation of Korea (Grant No. NRF-2015R1D1A1A01057931).

Publisher Copyright:
© 2017 The Korean Society of Applied Pharmacology.


  • Anticoagulant
  • Heparin
  • Venous thromboembolism
  • Vitamin K antagonist


Dive into the research topics of 'New anticoagulants for the prevention and treatment of venous thromboembolism'. Together they form a unique fingerprint.

Cite this